Supported by
high5immunology.tv | Rheumatology | EULAR 2025
Spotlight Discussions RA - ENG
ENG
EULAR 2025
Interfering on the long run: less difficult-to-treat…
ENG
ALTO, ARIAA
EULAR 2025
Preventing, delaying or early sufficient treatment of…
ENG
JAK-POT, NOR-DMARD
EULAR 2025
What about malignancies with JAKi treatment?
Spotlight Discussions PMR - ENG
ENG
EULAR 2025
Benefit of MTX underpinned in newly diagnosed PMR!
Spotlight Discussions axSpA - ENG
ENG
APEX
EULAR 2025
Cardiovascular impact of GLP-1 receptor agonists in…
Spotlight Discussions PsA - ENG
ENG
AGRO
EULAR 2025
IL-17A/IL-17F-inhibiting nanobody as a new molecule in…
ENG
APEX
EULAR 2025
TYK2-Inhibitors a new oral treatment option?
ENG
APEX
EULAR 2025
Real world data of Adalimumab vs Ixekizumab in PsA
Spotlight Discussions axSpA - ENG
ENG
APEX
EULAR 2025
Cardiovascular impact of GLP-1 receptor agonists in…
axSpA 100 sec - ENG
ENG
BE MOBILE 1 & 2
EULAR 2025
Sex-specific response on biologics
ENG
EULAR 2025
Impact of biologics on cardiovascular outcome in AS
ENG
EULAR 2025
The IL-17 story continues!
ENG
EULAR 2025
New bispecific antibodies against axSpA?
ENG
EULAR 2025
Effect of TNF inhibitors on the risk of cancer…
ENG
BE MOBILE 1 & 2
EULAR 2025
Subjective or objective endpoints - is there a…
ENG
EULAR 2025
Cancer reactivation in axSpA patients treated with…
ENG
TORTUGA
EULAR 2025
Connection between pain and disease activity
ENG
EULAR 2025
Impact of GLP-1 receptor agonists on cardiovascular…
axSpA 100 sec - multi language
GER
BE MOBILE 1 & 2
EULAR 2025
Subjektive oder objektive Endpunkte - gibt es eine…
GER
BE MOBILE 1 & 2
EULAR 2025
Geschlechtsspezifisches Ansprechen auf Biologika
ITA
EULAR 2025
Effetti degli inibitori del TNF sul rischio di recidiva…
ITA
EULAR 2025
Impatto degli agonisti del recettore GLP-1 sugli eventi…
GER
EULAR 2025
Neue bispezifische Antikörper gegen axSpA?
GER
EULAR 2025
Die IL-17-Story geht weiter!
GER
EULAR 2025
Krebs-Reaktivierung bei mit TNF-Blockern behandelten…
GER
TORTUGA
EULAR 2025
Zusammenhang von Schmerz und Krankheitsaktivität
ITA
EULAR 2025
Impatto dei farmaci biologici sugli esiti…
Spotlight Discussions PsA - ENG
ENG
AGRO
EULAR 2025
IL-17A/IL-17F-inhibiting nanobody as a new molecule in…
ENG
APEX
EULAR 2025
TYK2-Inhibitors a new oral treatment option?
ENG
APEX
EULAR 2025
Real world data of Adalimumab vs Ixekizumab in PsA
PsA 100 sec - ENG
ENG
EULAR 2025
Difficult-to-treat patients in active PsA
ENG
EULAR 2025
High prevalence of PsA in PsO patients without…
ENG
EULAR 2025
Definitions and prevalence of difficult-to-treat PsA
ENG
COMPLETE PsA
EULAR 2025
MTX+LEF strategy vs MTX alone in PsA
ENG
POETYK PsA-2
EULAR 2025
TYK2 inhibitors in PsA
ENG
POETYK PsA-2
EULAR 2025
TYK2: convenient, safe and effective!
ENG
ARGO
EULAR 2025
Sonelokimab, a novel IL-17A- and IL-17F-inhibiting…
ENG
EULAR 2025
Sexual health in patients with PsA
ENG
ARGO
EULAR 2025
Sonelokimab - again IL-17 inhibition or new IL-17…
ENG
STAMP
EULAR 2025
Hit hard & early or tight control - two ways to reach…
ENG
APEX
EULAR 2025
IL-23 stops radiographic progress
PsA 100 sec - multi language
GER
ARGO
EULAR 2025
Sonelokimab - schon wieder IL-17-Inhibition oder neue…
ITA
EULAR 2025
Difficult-to-treat patients in active PsA
GER
POETYK PsA-2
EULAR 2025
TYK2: bequem, sicher und auch wirksam!
FRA
COMPLETE PsA
EULAR 2025
Stratégie MTX+LEF vs MTX seul dans le rhumatisme…
GER
APEX
EULAR 2025
IL-23 stoppt radiografischen Progress
ESP
EULAR 2025
Definición y prevalencia de la APs difícil de tratar
GER
STAMP
EULAR 2025
Hit Hard & Early oder Tight Control - zwei Wege zum…
FRA
EULAR 2025
Santé sexuelle au cours du rhumatisme psoriasique
ITA
ARGO
EULAR 2025
Sonelokimab, a novel IL-17A- and IL-17F-inhibiting…
GER
EULAR 2025
Hohe Prävalenz von PsA bei PsO-Patienten ohne…
GER
POETYK PsA-2
EULAR 2025
TYK2-Inhibitoren bei PsA
Spotlight Discussions RA - ENG
ENG
EULAR 2025
Interfering on the long run: less difficult-to-treat…
ENG
JAK-POT, NOR-DMARD
EULAR 2025
What about malignancies with JAKi treatment?
ENG
ALTO, ARIAA
EULAR 2025
Preventing, delaying or early sufficient treatment of…
RA 100 sec - ENG
ENG
EULAR 2025
Cancer risk under biologic therapy in RA
ENG
JAK-POT
EULAR 2025
Cancer incidence in RA from the JAK-POT study
ENG
EULAR 2025
Safety of JAKies in RA
ENG
RESET-RA
EULAR 2025
New treatment options in RA
ENG
ALTO
EULAR 2025
Abatacept in individuals at risk of delevoping RA
ENG
ARIAA, ALTO
EULAR 2025
Prophylactic therapy with abatacept in patients at risk…
ENG
EULAR 2025
ILD in rheumatoid arthritis
RA 100 sec - multi language
ESP
ALTO
EULAR 2025
Abatacept en individuos en riesgo de desarrollar AR
NOR
JAK-POT
EULAR 2025
Cancer incidence in RA from the JAK-POT study
GER
ARIAA, ALTO
EULAR 2025
Prophylaktische Therapie mit Abatacept bei Patienten…
FRA
EULAR 2025
Risque de cancer sous biomédicament dans la PR
Spotlight Discussions PMR - ENG
ENG
EULAR 2025
Benefit of MTX underpinned in newly diagnosed PMR!
PMR 100 sec - ENG
ENG
EULAR 2025
Benefit of MTX underpinned in newly diagnosed PMR
PMR 100 sec - multi language
GER
EULAR 2025
Benefit von MTX bei neu diagnostizierter PMR…
Gout 100 sec - ENG
ENG
EULAR 2025
Cardiovascular outcomes of treat-to-target…
Gout 100 sec - multi language
ESP
EULAR 2025
Desenlaces cardiovasculares del tratamiento por…
Cross-cutting highlights 100 sec - ENG
ENG
DANBIO
EULAR 2025
Patient history matters: real-world data of infliximab…
ENG
EULAR 2025
Combination therapies in immune mediated inflammatory…
ENG
EULAR 2025
New therapeutic approach for refractory myositis
ENG
Nor-Drum
EULAR 2025
Cost-effectiveness of therapeutic drug monitoring
ENG
NOR-DMARD
EULAR 2025
Cancer mortality in inflammatory joint diseases
Cross-cutting highlights 100 sec - multi language
NOR
NOR-DMARD
EULAR 2025
Cancer mortality in inflammatory joint diseases
GER
DANBIO
EULAR 2025
Die Patientengeschichte zählt: Infliximab-Biosimilar…
NOR
Nor-Drum
EULAR 2025
Cost-effectiveness of therapeutic drug monitoring
GER
EULAR 2025
Neuer Therapieansatz für refrakträre Myositis
GER
EULAR 2025
Kombinationstherapien bei immunvermittelten…
